477 related articles for article (PubMed ID: 25257673)
21. [Methylprednisolone pulse therapy in Kawasaki disease].
Miura M; Matsuoka M; Kohno K; Ohki H; Yoshiba S
Nihon Rinsho; 2008 Feb; 66(2):338-42. PubMed ID: 18265457
[TBL] [Abstract][Full Text] [Related]
22. Infliximab Plus Intravenous Immunoglobulin (IVIG) Versus IVIG Alone as Initial Therapy in Children With Kawasaki Disease Presenting With Coronary Artery Lesions: Is Dual Therapy More Effective?
Jone PN; Anderson MS; Mulvahill MJ; Heizer H; Glodé MP; Dominguez SR
Pediatr Infect Dis J; 2018 Oct; 37(10):976-980. PubMed ID: 29461447
[TBL] [Abstract][Full Text] [Related]
23. Neutropenia after intravenous immunoglobulin therapy is associated with coronary artery lesions in children with Kawasaki disease: a case control study.
Wang Z; Weng F; Li C; Shi H; Tang Z; Qiu H; He Y; Wu R; Chu M
BMC Pediatr; 2018 Feb; 18(1):76. PubMed ID: 29466965
[TBL] [Abstract][Full Text] [Related]
24. The role of serum lipid in predicting coronary artery lesions and intravenous immunoglobulin resistance in Kawasaki disease: a cohort study.
Zhang H; Cai J; Zhang R; Shuai S; Tang M; Ju R; Hu Y; Zuo T; Yang Y
J Int Med Res; 2024 May; 52(5):3000605241252115. PubMed ID: 38713460
[TBL] [Abstract][Full Text] [Related]
25. Coronary artery lesions and the increasing incidence of Kawasaki disease resistant to initial immunoglobulin.
Kibata T; Suzuki Y; Hasegawa S; Matsushige T; Kusuda T; Hoshide M; Takahashi K; Okada S; Wakiguchi H; Moriwake T; Uchida M; Ohbuchi N; Iwai T; Hasegawa M; Ichihara K; Yashiro M; Makino N; Nakamura Y; Ohga S
Int J Cardiol; 2016 Jul; 214():209-15. PubMed ID: 27070994
[TBL] [Abstract][Full Text] [Related]
26. Correlations of complication with coronary arterial lesion with VEGF, PLT, D-dimer and inflammatory factor in child patients with Kawasaki disease.
Zhou Y; Wang S; Zhao J; Fang P
Eur Rev Med Pharmacol Sci; 2018 Aug; 22(16):5121-5126. PubMed ID: 30178831
[TBL] [Abstract][Full Text] [Related]
27. Clinical relevance of the risk factors for coronary artery lesions in Kawasaki disease.
Weng KP; Hsieh KS; Huang SH; Ou SF; Ma CY; Ho TY; Lai CR; Ger LP
Kaohsiung J Med Sci; 2012 Jan; 28(1):23-9. PubMed ID: 22226058
[TBL] [Abstract][Full Text] [Related]
28. Association of Genetic Polymorphisms in Kawasaki Disease with the Response to Intravenous Immunoglobulin Therapy.
Sapountzi E; Fidani L; Giannopoulos A; Galli-Tsinopoulou A
Pediatr Cardiol; 2023 Jan; 44(1):1-12. PubMed ID: 35908117
[TBL] [Abstract][Full Text] [Related]
29. [Risk factors for coronary artery lesions secondary to Kawasaki disease in children].
Deng YC; Wang X; Tang XC; Huang CZ; Yang J; Mo LY
Zhongguo Dang Dai Er Ke Za Zhi; 2015 Sep; 17(9):927-31. PubMed ID: 26412172
[TBL] [Abstract][Full Text] [Related]
30. Timing of intravenous immunoglobulin treatment and risk of coronary artery abnormalities in children with Kawasaki disease.
Bal AK; Prasad D; Umali Pamintuan MA; Mammen-Prasad E; Petrova A
Pediatr Neonatol; 2014 Oct; 55(5):387-92. PubMed ID: 24636168
[TBL] [Abstract][Full Text] [Related]
31. Kawasaki disease in Sicily: clinical description and markers of disease severity.
Maggio MC; Corsello G; Prinzi E; Cimaz R
Ital J Pediatr; 2016 Nov; 42(1):92. PubMed ID: 27806720
[TBL] [Abstract][Full Text] [Related]
32. [Plasma exchange therapy for Kawasaki disease refractory to intravenous immunoglobulin].
Mori M
Nihon Rinsho; 2008 Feb; 66(2):349-54. PubMed ID: 18260334
[TBL] [Abstract][Full Text] [Related]
33. [Changes of P-selectin and E-selectin in children with Kawasaki disease].
Qiu Y; Wu J; Fang XY; Lin Z; Wu BY; Cai RY; Xu XY; Zheng H
Zhonghua Er Ke Za Zhi; 2004 Sep; 42(9):688-92. PubMed ID: 15482673
[TBL] [Abstract][Full Text] [Related]
34. Acute and late coronary outcomes in 1073 patients with Kawasaki disease with and without intravenous γ-immunoglobulin therapy.
Lin MT; Sun LC; Wu ET; Wang JK; Lue HC; Wu MH
Arch Dis Child; 2015 Jun; 100(6):542-7. PubMed ID: 25564534
[TBL] [Abstract][Full Text] [Related]
35. High-Dose Aspirin is Associated with Anemia and Does Not Confer Benefit to Disease Outcomes in Kawasaki Disease.
Kuo HC; Lo MH; Hsieh KS; Guo MM; Huang YH
PLoS One; 2015; 10(12):e0144603. PubMed ID: 26658843
[TBL] [Abstract][Full Text] [Related]
36. [Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study].
Qin LJ; Wang HW; Hu XF; Liu QJ; Shi H; Wei YX; Chen QJ; Cheng PX
Zhonghua Er Ke Za Zhi; 2006 Dec; 44(12):891-5. PubMed ID: 17254453
[TBL] [Abstract][Full Text] [Related]
37. Increased Pentraxin 3 Levels Correlate With IVIG Responsiveness and Coronary Artery Aneurysm Formation in Kawasaki Disease.
Kitoh T; Ohara T; Muto T; Okumura A; Baba R; Koizumi Y; Yamagishi Y; Mikamo H; Daigo K; Hamakubo T
Front Immunol; 2021; 12():624802. PubMed ID: 33912155
[TBL] [Abstract][Full Text] [Related]
38. Serum albumin level predicts initial intravenous immunoglobulin treatment failure in Kawasaki disease.
Kuo HC; Liang CD; Wang CL; Yu HR; Hwang KP; Yang KD
Acta Paediatr; 2010 Oct; 99(10):1578-83. PubMed ID: 20491705
[TBL] [Abstract][Full Text] [Related]
39. Treatment of Kawasaki disease with a moderate dose (1 g/kg) of intravenous immunoglobulin.
Khowsathit P; Hong-Hgam C; Khositseth A; Wanitkun S
J Med Assoc Thai; 2002 Nov; 85 Suppl 4():S1121-6. PubMed ID: 12549785
[TBL] [Abstract][Full Text] [Related]
40. Long-term efficacy of plasma exchange treatment for refractory Kawasaki disease.
Hokosaki T; Mori M; Nishizawa T; Nakamura T; Imagawa T; Iwamoto M; Yokota S
Pediatr Int; 2012 Feb; 54(1):99-103. PubMed ID: 22004042
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
